|

TYRA-300 Dose TBD Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • Tyra Biosciences, Inc1

Indications

  • FGFR3 Gene Fusions1
  • FGFR3 Gene Mutation1
  • FGFR3 Gene Alteration1
  • FGFR Gene Alterations1
  • FGFR Gene Amplification1

Homewood, Alabama1 trial

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Urology Centers of Alabama

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.